 Rangaraj Selvarangan
Concepts (481)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 18 | 2022 | 34 | 7.940 |
Why?
| | Parechovirus | 14 | 2021 | 17 | 7.010 |
Why?
| | Enterovirus Infections | 16 | 2022 | 28 | 6.860 |
Why?
| | Picornaviridae Infections | 13 | 2021 | 18 | 6.680 |
Why?
| | Respiratory Tract Infections | 16 | 2022 | 56 | 6.150 |
Why?
| | Molecular Diagnostic Techniques | 13 | 2021 | 36 | 5.970 |
Why?
| | Influenza A virus | 10 | 2020 | 17 | 5.790 |
Why?
| | Infant | 78 | 2022 | 1371 | 5.380 |
Why?
| | Humans | 135 | 2022 | 5964 | 5.280 |
Why?
| | Influenza B virus | 11 | 2022 | 18 | 5.100 |
Why?
| | Respiratory Syncytial Virus Infections | 10 | 2022 | 37 | 5.020 |
Why?
| | Child | 82 | 2022 | 2796 | 4.480 |
Why?
| | Child, Preschool | 69 | 2022 | 1442 | 4.370 |
Why?
| | Nucleic Acid Amplification Techniques | 6 | 2020 | 13 | 4.080 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2022 | 18 | 4.020 |
Why?
| | Enterovirus D, Human | 11 | 2022 | 20 | 3.760 |
Why?
| | Enterovirus | 6 | 2021 | 8 | 3.670 |
Why?
| | Sensitivity and Specificity | 28 | 2021 | 142 | 3.380 |
Why?
| | Anti-Bacterial Agents | 17 | 2021 | 232 | 3.240 |
Why?
| | Gastroenteritis | 13 | 2021 | 21 | 3.210 |
Why?
| | Female | 71 | 2021 | 3320 | 3.110 |
Why?
| | Male | 66 | 2021 | 3237 | 3.030 |
Why?
| | Disease Outbreaks | 10 | 2022 | 23 | 2.870 |
Why?
| | Adolescent | 45 | 2022 | 1931 | 2.740 |
Why?
| | Central Nervous System Infections | 3 | 2021 | 5 | 2.670 |
Why?
| | United States | 40 | 2022 | 621 | 2.660 |
Why?
| | Diagnostic Tests, Routine | 5 | 2019 | 18 | 2.600 |
Why?
| | Real-Time Polymerase Chain Reaction | 8 | 2020 | 33 | 2.570 |
Why?
| | Infant, Newborn | 33 | 2021 | 877 | 2.570 |
Why?
| | Nasopharynx | 10 | 2021 | 23 | 2.300 |
Why?
| | Feces | 15 | 2021 | 33 | 2.210 |
Why?
| | Antibodies, Viral | 9 | 2022 | 35 | 2.190 |
Why?
| | Bacteremia | 5 | 2021 | 26 | 2.130 |
Why?
| | Streptococcal Infections | 4 | 2020 | 20 | 2.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 10 | 2020 | 87 | 1.980 |
Why?
| | Prospective Studies | 19 | 2021 | 460 | 1.930 |
Why?
| | Reagent Kits, Diagnostic | 9 | 2018 | 12 | 1.900 |
Why?
| | Hospitalization | 16 | 2022 | 170 | 1.860 |
Why?
| | Virology | 5 | 2015 | 5 | 1.740 |
Why?
| | Urinary Tract Infections | 3 | 2021 | 22 | 1.700 |
Why?
| | Rotavirus Vaccines | 7 | 2019 | 10 | 1.650 |
Why?
| | Young Adult | 18 | 2021 | 582 | 1.640 |
Why?
| | Polymerase Chain Reaction | 7 | 2019 | 98 | 1.580 |
Why?
| | Bacteriological Techniques | 5 | 2021 | 7 | 1.560 |
Why?
| | DNA, Viral | 4 | 2020 | 13 | 1.540 |
Why?
| | Point-of-Care Testing | 2 | 2020 | 7 | 1.540 |
Why?
| | Adult | 22 | 2021 | 1082 | 1.530 |
Why?
| | Sepsis | 4 | 2018 | 24 | 1.510 |
Why?
| | Rotavirus Infections | 9 | 2021 | 11 | 1.500 |
Why?
| | Middle Aged | 16 | 2021 | 551 | 1.450 |
Why?
| | Mycoplasma pneumoniae | 5 | 2020 | 12 | 1.440 |
Why?
| | Pneumonia, Mycoplasma | 5 | 2020 | 13 | 1.440 |
Why?
| | Aged | 13 | 2021 | 302 | 1.420 |
Why?
| | Clostridium Infections | 3 | 2020 | 7 | 1.390 |
Why?
| | Aged, 80 and over | 10 | 2021 | 115 | 1.370 |
Why?
| | Emergency Service, Hospital | 6 | 2022 | 120 | 1.350 |
Why?
| | Retrospective Studies | 18 | 2022 | 1166 | 1.340 |
Why?
| | Specimen Handling | 5 | 2021 | 17 | 1.320 |
Why?
| | Staphylococcal Infections | 4 | 2016 | 23 | 1.310 |
Why?
| | Staphylococcus aureus | 3 | 2016 | 19 | 1.290 |
Why?
| | Norovirus | 4 | 2021 | 5 | 1.260 |
Why?
| | Respiratory System | 3 | 2015 | 5 | 1.230 |
Why?
| | Cerebrospinal Fluid | 4 | 2020 | 8 | 1.220 |
Why?
| | Immunoassay | 4 | 2015 | 10 | 1.190 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2020 | 44 | 1.170 |
Why?
| | Point-of-Care Systems | 3 | 2020 | 14 | 1.170 |
Why?
| | Genotype | 16 | 2021 | 298 | 1.150 |
Why?
| | Influenza Vaccines | 5 | 2022 | 14 | 1.120 |
Why?
| | Bodily Secretions | 2 | 2015 | 3 | 1.120 |
Why?
| | Caliciviridae Infections | 3 | 2021 | 4 | 1.090 |
Why?
| | Antibodies, Neutralizing | 4 | 2022 | 29 | 1.070 |
Why?
| | Streptococcus pyogenes | 3 | 2020 | 13 | 1.070 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2021 | 11 | 1.060 |
Why?
| | Enterobacteriaceae | 2 | 2021 | 5 | 1.060 |
Why?
| | Missouri | 8 | 2022 | 83 | 1.060 |
Why?
| | Rhinovirus | 2 | 2020 | 6 | 1.010 |
Why?
| | Vancomycin Resistance | 2 | 2014 | 4 | 1.010 |
Why?
| | Escherichia coli | 11 | 2017 | 33 | 1.000 |
Why?
| | Virus Diseases | 2 | 2020 | 11 | 0.990 |
Why?
| | Inpatients | 3 | 2020 | 49 | 0.970 |
Why?
| | Automation, Laboratory | 2 | 2019 | 3 | 0.960 |
Why?
| | Coinfection | 1 | 2022 | 5 | 0.960 |
Why?
| | Rotavirus | 6 | 2021 | 7 | 0.960 |
Why?
| | Population Surveillance | 6 | 2021 | 12 | 0.950 |
Why?
| | Time Factors | 9 | 2020 | 269 | 0.940 |
Why?
| | Pharyngitis | 2 | 2020 | 13 | 0.920 |
Why?
| | Multiplex Polymerase Chain Reaction | 2 | 2018 | 6 | 0.920 |
Why?
| | Cephalosporins | 2 | 2021 | 15 | 0.910 |
Why?
| | Itraconazole | 2 | 2020 | 2 | 0.910 |
Why?
| | Triazoles | 2 | 2020 | 4 | 0.910 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2022 | 7 | 0.910 |
Why?
| | Clinical Laboratory Techniques | 5 | 2021 | 9 | 0.890 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 12 | 0.880 |
Why?
| | Microbial Sensitivity Tests | 12 | 2021 | 34 | 0.880 |
Why?
| | Mass Screening | 2 | 2019 | 40 | 0.880 |
Why?
| | Bacterial Infections | 1 | 2021 | 29 | 0.870 |
Why?
| | Phlebotomy | 2 | 2011 | 2 | 0.860 |
Why?
| | Equipment Contamination | 2 | 2011 | 6 | 0.850 |
Why?
| | Antiviral Agents | 4 | 2021 | 23 | 0.850 |
Why?
| | Prevalence | 11 | 2021 | 136 | 0.850 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2020 | 4 | 0.840 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 4 | 0.830 |
Why?
| | RNA Viruses | 1 | 2019 | 3 | 0.810 |
Why?
| | Urinalysis | 1 | 2019 | 6 | 0.790 |
Why?
| | Phylogeny | 9 | 2021 | 18 | 0.790 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2019 | 3 | 0.780 |
Why?
| | Communicable Diseases, Emerging | 1 | 2019 | 3 | 0.770 |
Why?
| | Antigens, Viral | 3 | 2015 | 6 | 0.770 |
Why?
| | Peritonitis | 2 | 2021 | 53 | 0.760 |
Why?
| | Drug Utilization | 1 | 2018 | 14 | 0.740 |
Why?
| | Molecular Typing | 1 | 2018 | 2 | 0.740 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2015 | 14 | 0.730 |
Why?
| | Bordetella Infections | 2 | 2014 | 2 | 0.690 |
Why?
| | Bordetella parapertussis | 2 | 2014 | 2 | 0.690 |
Why?
| | Peritoneal Dialysis | 2 | 2021 | 148 | 0.690 |
Why?
| | Viral Vaccines | 2 | 2022 | 8 | 0.680 |
Why?
| | Severity of Illness Index | 6 | 2021 | 145 | 0.670 |
Why?
| | Escherichia coli Infections | 7 | 2017 | 18 | 0.670 |
Why?
| | Carrier State | 2 | 2018 | 5 | 0.660 |
Why?
| | Adhesins, Escherichia coli | 9 | 2017 | 9 | 0.650 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2016 | 16 | 0.630 |
Why?
| | Fever | 4 | 2021 | 26 | 0.620 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 10 | 0.600 |
Why?
| | Drug Resistance, Bacterial | 5 | 2020 | 15 | 0.600 |
Why?
| | Sequence Analysis, DNA | 7 | 2019 | 102 | 0.600 |
Why?
| | Herpes Simplex | 2 | 2020 | 8 | 0.590 |
Why?
| | RNA, Viral | 3 | 2015 | 18 | 0.580 |
Why?
| | Pharynx | 3 | 2020 | 7 | 0.580 |
Why?
| | Mycoplasma | 1 | 2015 | 2 | 0.580 |
Why?
| | Mycoplasma Infections | 1 | 2015 | 2 | 0.580 |
Why?
| | Antigens, Bacterial | 3 | 2011 | 9 | 0.570 |
Why?
| | Kansas | 3 | 2022 | 45 | 0.560 |
Why?
| | Bordetella pertussis | 1 | 2014 | 1 | 0.560 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 19 | 0.560 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 3 | 0.560 |
Why?
| | Macrolides | 5 | 2020 | 7 | 0.540 |
Why?
| | Blood Specimen Collection | 2 | 2011 | 4 | 0.540 |
Why?
| | Case-Control Studies | 8 | 2022 | 129 | 0.540 |
Why?
| | Seasons | 6 | 2022 | 16 | 0.540 |
Why?
| | Vaccination | 7 | 2022 | 42 | 0.530 |
Why?
| | Adenovirus Infections, Human | 2 | 2011 | 3 | 0.530 |
Why?
| | Vancomycin | 1 | 2014 | 17 | 0.530 |
Why?
| | Virus Cultivation | 4 | 2015 | 4 | 0.530 |
Why?
| | Animals | 12 | 2022 | 884 | 0.520 |
Why?
| | Candida | 2 | 2003 | 3 | 0.520 |
Why?
| | Genetic Variation | 3 | 2022 | 144 | 0.490 |
Why?
| | Pandemics | 3 | 2022 | 56 | 0.490 |
Why?
| | Enterococcus | 1 | 2012 | 3 | 0.480 |
Why?
| | Risk Factors | 7 | 2020 | 389 | 0.470 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2012 | 8 | 0.470 |
Why?
| | Paramyxoviridae | 1 | 2011 | 1 | 0.470 |
Why?
| | Streptococcus bovis | 1 | 2011 | 1 | 0.460 |
Why?
| | Paramyxoviridae Infections | 1 | 2011 | 10 | 0.460 |
Why?
| | Meningitis, Bacterial | 1 | 2011 | 6 | 0.460 |
Why?
| | Oligonucleotide Probes | 2 | 2009 | 8 | 0.450 |
Why?
| | Campylobacter Infections | 1 | 2011 | 2 | 0.450 |
Why?
| | False Positive Reactions | 1 | 2011 | 5 | 0.450 |
Why?
| | Adenoviruses, Human | 1 | 2011 | 1 | 0.450 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 7 | 0.440 |
Why?
| | Blood | 1 | 2011 | 13 | 0.440 |
Why?
| | Catheterization, Peripheral | 1 | 2011 | 5 | 0.440 |
Why?
| | Meningitis, Viral | 2 | 2022 | 2 | 0.430 |
Why?
| | Follow-Up Studies | 5 | 2021 | 307 | 0.420 |
Why?
| | Pediatric Nursing | 1 | 2010 | 4 | 0.420 |
Why?
| | Infection Control | 1 | 2010 | 7 | 0.410 |
Why?
| | Genotyping Techniques | 2 | 2020 | 18 | 0.410 |
Why?
| | Pyelonephritis | 4 | 2004 | 5 | 0.390 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2022 | 6 | 0.390 |
Why?
| | Epidemiological Monitoring | 5 | 2021 | 6 | 0.390 |
Why?
| | Encephalitis, Viral | 1 | 2009 | 1 | 0.390 |
Why?
| | Simplexvirus | 1 | 2009 | 3 | 0.380 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 4 | 0.380 |
Why?
| | Antifungal Agents | 2 | 2020 | 12 | 0.380 |
Why?
| | Mycobacterium | 2 | 2010 | 2 | 0.380 |
Why?
| | Streptococcus pneumoniae | 1 | 2009 | 16 | 0.370 |
Why?
| | Enterobacteriaceae Infections | 2 | 2018 | 8 | 0.360 |
Why?
| | Predictive Value of Tests | 4 | 2019 | 100 | 0.350 |
Why?
| | Adhesins, Bacterial | 2 | 2004 | 2 | 0.340 |
Why?
| | Reproducibility of Results | 3 | 2012 | 182 | 0.330 |
Why?
| | beta-Lactamases | 3 | 2018 | 6 | 0.320 |
Why?
| | Candida albicans | 2 | 2003 | 4 | 0.320 |
Why?
| | Fucosyltransferases | 2 | 2015 | 2 | 0.300 |
Why?
| | Algorithms | 3 | 2020 | 96 | 0.300 |
Why?
| | Cluster Analysis | 4 | 2015 | 30 | 0.290 |
Why?
| | Immunization Programs | 2 | 2019 | 6 | 0.290 |
Why?
| | Cross Infection | 2 | 2017 | 13 | 0.280 |
Why?
| | Collagen Type IV | 1 | 2004 | 2 | 0.280 |
Why?
| | Escherichia coli Proteins | 1 | 2004 | 2 | 0.280 |
Why?
| | Fimbriae, Bacterial | 4 | 2001 | 4 | 0.280 |
Why?
| | Cephalosporin Resistance | 3 | 2018 | 4 | 0.270 |
Why?
| | Saliva | 2 | 2021 | 9 | 0.270 |
Why?
| | Longitudinal Studies | 2 | 2020 | 124 | 0.250 |
Why?
| | Cohort Studies | 3 | 2021 | 256 | 0.250 |
Why?
| | Acute Disease | 2 | 2020 | 62 | 0.250 |
Why?
| | DNA Probes | 1 | 2002 | 3 | 0.250 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 7 | 0.250 |
Why?
| | Oseltamivir | 2 | 2021 | 6 | 0.250 |
Why?
| | Viral Fusion Proteins | 1 | 2022 | 4 | 0.240 |
Why?
| | Seroepidemiologic Studies | 2 | 2019 | 3 | 0.240 |
Why?
| | Craniocerebral Trauma | 1 | 2022 | 15 | 0.240 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 24 | 0.240 |
Why?
| | Midwestern United States | 2 | 2013 | 41 | 0.240 |
Why?
| | Hospitals, Pediatric | 3 | 2020 | 176 | 0.230 |
Why?
| | Child, Hospitalized | 3 | 2022 | 27 | 0.230 |
Why?
| | Critical Care | 3 | 2018 | 12 | 0.230 |
Why?
| | Vaccines | 1 | 2021 | 13 | 0.230 |
Why?
| | Herpesvirus 1, Cercopithecine | 1 | 2021 | 1 | 0.230 |
Why?
| | Central Nervous System | 1 | 2021 | 7 | 0.230 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.230 |
Why?
| | Child Abuse | 1 | 2022 | 42 | 0.230 |
Why?
| | Immunity, Humoral | 1 | 2021 | 6 | 0.230 |
Why?
| | Cloud Computing | 1 | 2021 | 5 | 0.220 |
Why?
| | Risk Assessment | 2 | 2020 | 133 | 0.220 |
Why?
| | Lung Diseases | 1 | 2021 | 42 | 0.220 |
Why?
| | Disease Management | 2 | 2018 | 36 | 0.220 |
Why?
| | Lymphadenitis | 2 | 2013 | 3 | 0.220 |
Why?
| | Public Health Surveillance | 1 | 2020 | 4 | 0.220 |
Why?
| | Klebsiella Infections | 2 | 2017 | 3 | 0.210 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 31 | 0.210 |
Why?
| | ROC Curve | 1 | 2020 | 18 | 0.210 |
Why?
| | Quebec | 1 | 2020 | 4 | 0.210 |
Why?
| | Herpesvirus 1, Human | 1 | 2020 | 2 | 0.210 |
Why?
| | Drug Resistance, Viral | 1 | 2020 | 3 | 0.210 |
Why?
| | Coronavirus Infections | 1 | 2020 | 15 | 0.210 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2020 | 3 | 0.210 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 16 | 0.210 |
Why?
| | DNA, Bacterial | 3 | 2011 | 5 | 0.210 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.210 |
Why?
| | Canada | 1 | 2020 | 33 | 0.210 |
Why?
| | International Classification of Diseases | 1 | 2020 | 8 | 0.210 |
Why?
| | Family Health | 1 | 2020 | 14 | 0.210 |
Why?
| | Gastrointestinal Diseases | 1 | 2021 | 55 | 0.210 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 23 | 0.210 |
Why?
| | Postoperative Care | 1 | 2020 | 29 | 0.200 |
Why?
| | Europe | 1 | 2020 | 30 | 0.200 |
Why?
| | Early Diagnosis | 1 | 2020 | 35 | 0.200 |
Why?
| | Immunoenzyme Techniques | 1 | 2019 | 12 | 0.200 |
Why?
| | Age Distribution | 1 | 2019 | 32 | 0.200 |
Why?
| | Prognosis | 1 | 2020 | 179 | 0.200 |
Why?
| | Gonorrhea | 2 | 2015 | 4 | 0.190 |
Why?
| | Molecular Epidemiology | 3 | 2017 | 6 | 0.190 |
Why?
| | History, 21st Century | 1 | 2019 | 6 | 0.190 |
Why?
| | Chronic Disease | 3 | 2012 | 104 | 0.190 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 3 | 0.190 |
Why?
| | Bacterial Typing Techniques | 2 | 2016 | 4 | 0.190 |
Why?
| | Immunization Schedule | 1 | 2019 | 7 | 0.190 |
Why?
| | Critical Pathways | 1 | 2018 | 9 | 0.190 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.190 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 9 | 0.190 |
Why?
| | False Negative Reactions | 1 | 2018 | 11 | 0.180 |
Why?
| | Intestines | 1 | 2018 | 27 | 0.180 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2017 | 2 | 0.180 |
Why?
| | Sapovirus | 1 | 2017 | 1 | 0.170 |
Why?
| | Cell Line | 1 | 2017 | 104 | 0.170 |
Why?
| | Cells, Cultured | 1 | 2017 | 113 | 0.170 |
Why?
| | Klebsiella pneumoniae | 1 | 2017 | 2 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 99 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 145 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 30 | 0.170 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 95 | 0.170 |
Why?
| | Neoplasms | 1 | 2018 | 90 | 0.160 |
Why?
| | Staphylococcal Skin Infections | 1 | 2016 | 3 | 0.160 |
Why?
| | Clindamycin | 1 | 2016 | 3 | 0.160 |
Why?
| | Length of Stay | 2 | 2018 | 231 | 0.160 |
Why?
| | Recombination, Genetic | 1 | 2015 | 4 | 0.150 |
Why?
| | Virulence Factors | 1 | 2015 | 4 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2015 | 13 | 0.150 |
Why?
| | Hemoglobins | 1 | 2015 | 22 | 0.150 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 2 | 0.150 |
Why?
| | Trichomonas Vaginitis | 1 | 2015 | 2 | 0.150 |
Why?
| | Chlamydia Infections | 1 | 2015 | 3 | 0.150 |
Why?
| | Equipment Failure | 1 | 2015 | 8 | 0.140 |
Why?
| | Dogs | 1 | 2015 | 17 | 0.140 |
Why?
| | DNA, Ribosomal | 2 | 2011 | 3 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2011 | 7 | 0.140 |
Why?
| | Unnecessary Procedures | 1 | 2015 | 15 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2018 | 615 | 0.140 |
Why?
| | Quality Improvement | 1 | 2015 | 63 | 0.140 |
Why?
| | HeLa Cells | 6 | 2004 | 21 | 0.140 |
Why?
| | Base Sequence | 2 | 2004 | 114 | 0.130 |
Why?
| | Age Factors | 3 | 2021 | 223 | 0.130 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 120 | 0.130 |
Why?
| | DNA, Fungal | 2 | 2003 | 5 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 8 | 0.130 |
Why?
| | Viral Proteins | 1 | 2013 | 19 | 0.130 |
Why?
| | Incidence | 2 | 2011 | 130 | 0.130 |
Why?
| | Abscess | 1 | 2013 | 11 | 0.130 |
Why?
| | Diarrhea | 2 | 2011 | 16 | 0.130 |
Why?
| | Mice | 3 | 2022 | 441 | 0.130 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 18 | 0.120 |
Why?
| | Pneumococcal Infections | 2 | 2011 | 16 | 0.120 |
Why?
| | Vaccines, Attenuated | 3 | 2019 | 7 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 7 | 0.120 |
Why?
| | Epitopes | 2 | 2022 | 19 | 0.120 |
Why?
| | Enterotoxins | 1 | 2011 | 2 | 0.110 |
Why?
| | Middle Ear Ventilation | 1 | 2011 | 1 | 0.110 |
Why?
| | Exudates and Transudates | 1 | 2011 | 2 | 0.110 |
Why?
| | Operon | 3 | 2001 | 4 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2011 | 6 | 0.110 |
Why?
| | Campylobacter | 1 | 2011 | 2 | 0.110 |
Why?
| | Restriction Mapping | 1 | 2011 | 14 | 0.110 |
Why?
| | Serotyping | 1 | 2011 | 6 | 0.110 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 2 | 0.110 |
Why?
| | Policy Making | 1 | 2011 | 3 | 0.110 |
Why?
| | Immunocompromised Host | 2 | 2020 | 9 | 0.110 |
Why?
| | Cost of Illness | 2 | 2020 | 15 | 0.100 |
Why?
| | Quality of Health Care | 1 | 2010 | 18 | 0.100 |
Why?
| | Linear Models | 1 | 2010 | 54 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2011 | 176 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2019 | 278 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2005 | 80 | 0.100 |
Why?
| | Databases, Factual | 1 | 2010 | 106 | 0.100 |
Why?
| | Parents | 2 | 2021 | 126 | 0.100 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 1 | 0.100 |
Why?
| | Haemophilus Infections | 1 | 2009 | 5 | 0.100 |
Why?
| | Bacterial Proteins | 3 | 2017 | 8 | 0.090 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2010 | 43 | 0.090 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2008 | 2 | 0.090 |
Why?
| | Mutation | 3 | 2019 | 202 | 0.090 |
Why?
| | Biomarkers | 2 | 2021 | 117 | 0.090 |
Why?
| | DNA, Ribosomal Spacer | 2 | 2010 | 3 | 0.090 |
Why?
| | Temperature | 2 | 2010 | 11 | 0.090 |
Why?
| | Adenoviridae | 1 | 2007 | 4 | 0.090 |
Why?
| | Virulence | 2 | 2004 | 6 | 0.080 |
Why?
| | Mycobacterium Infections | 1 | 2006 | 1 | 0.080 |
Why?
| | Mice, Inbred C3H | 2 | 2004 | 10 | 0.080 |
Why?
| | Anemia, Sickle Cell | 1 | 2006 | 17 | 0.080 |
Why?
| | Illinois | 2 | 2015 | 4 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 24 | 0.070 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2001 | 29 | 0.070 |
Why?
| | Chromatography, Gas | 1 | 2004 | 1 | 0.070 |
Why?
| | Fatty Acids | 1 | 2004 | 4 | 0.070 |
Why?
| | Culture Media | 1 | 2003 | 1 | 0.070 |
Why?
| | Candida glabrata | 1 | 2003 | 1 | 0.070 |
Why?
| | Mycology | 1 | 2003 | 2 | 0.070 |
Why?
| | Gene Amplification | 1 | 2003 | 6 | 0.070 |
Why?
| | CHO Cells | 2 | 2002 | 4 | 0.070 |
Why?
| | Cricetinae | 2 | 2002 | 7 | 0.070 |
Why?
| | DNA Primers | 1 | 2003 | 41 | 0.070 |
Why?
| | Kidney | 1 | 2004 | 89 | 0.070 |
Why?
| | Phenotype | 1 | 2004 | 217 | 0.060 |
Why?
| | Mycological Typing Techniques | 1 | 2002 | 3 | 0.060 |
Why?
| | Candidiasis | 1 | 2002 | 5 | 0.060 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 9 | 0.060 |
Why?
| | Complement System Proteins | 1 | 2002 | 5 | 0.060 |
Why?
| | Macaca nemestrina | 1 | 2002 | 1 | 0.060 |
Why?
| | Trypanosoma cruzi | 1 | 2002 | 2 | 0.060 |
Why?
| | Chagas Disease | 1 | 2002 | 2 | 0.060 |
Why?
| | Hematoma, Subdural | 1 | 2022 | 4 | 0.060 |
Why?
| | Microbiological Techniques | 2 | 2015 | 5 | 0.060 |
Why?
| | Hospitals | 1 | 2022 | 36 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2021 | 9 | 0.060 |
Why?
| | Viral Load | 1 | 2021 | 22 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2021 | 7 | 0.060 |
Why?
| | Antibody Specificity | 1 | 2021 | 9 | 0.060 |
Why?
| | Cross Reactions | 1 | 2021 | 7 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2021 | 17 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 15 | 0.060 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 8 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2021 | 35 | 0.060 |
Why?
| | Transcriptome | 1 | 2021 | 34 | 0.060 |
Why?
| | Viruses | 1 | 2021 | 2 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2021 | 17 | 0.060 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.060 |
Why?
| | Microtubules | 2 | 1999 | 6 | 0.060 |
Why?
| | Bacteria | 1 | 2021 | 9 | 0.060 |
Why?
| | Immunization | 1 | 2021 | 21 | 0.060 |
Why?
| | Pregnancy | 4 | 2005 | 252 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 34 | 0.050 |
Why?
| | Comorbidity | 1 | 2021 | 68 | 0.050 |
Why?
| | Neck | 2 | 2013 | 4 | 0.050 |
Why?
| | Dialysis Solutions | 1 | 2021 | 19 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2021 | 27 | 0.050 |
Why?
| | Self Care | 1 | 2021 | 23 | 0.050 |
Why?
| | Catheterization | 1 | 2021 | 25 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2021 | 178 | 0.050 |
Why?
| | Skin | 1 | 2020 | 14 | 0.050 |
Why?
| | Family Characteristics | 1 | 2020 | 8 | 0.050 |
Why?
| | Vacuoles | 1 | 2000 | 1 | 0.050 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2000 | 1 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2020 | 34 | 0.050 |
Why?
| | RNA, Ribosomal, 23S | 1 | 2019 | 1 | 0.050 |
Why?
| | Liver | 1 | 2021 | 159 | 0.050 |
Why?
| | Cytoskeleton | 1 | 1999 | 3 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1999 | 28 | 0.050 |
Why?
| | Medically Uninsured | 1 | 2019 | 5 | 0.050 |
Why?
| | Premature Birth | 1 | 2019 | 5 | 0.050 |
Why?
| | Australia | 1 | 2019 | 8 | 0.050 |
Why?
| | Netherlands | 1 | 2019 | 5 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 205 | 0.050 |
Why?
| | Regression Analysis | 1 | 2018 | 59 | 0.050 |
Why?
| | Metabolic Diseases | 1 | 2018 | 13 | 0.050 |
Why?
| | Practice Patterns, Nurses' | 1 | 2017 | 5 | 0.040 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2017 | 1 | 0.040 |
Why?
| | beta-Lactam Resistance | 1 | 2017 | 1 | 0.040 |
Why?
| | Fimbriae Proteins | 1 | 2017 | 1 | 0.040 |
Why?
| | Penicillin-Binding Proteins | 1 | 2016 | 2 | 0.040 |
Why?
| | Pharmacy Service, Hospital | 1 | 2016 | 8 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 79 | 0.040 |
Why?
| | Sequence Homology | 1 | 2015 | 2 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2015 | 3 | 0.040 |
Why?
| | Genome, Viral | 1 | 2015 | 4 | 0.040 |
Why?
| | China | 1 | 2015 | 9 | 0.040 |
Why?
| | Dyspnea | 1 | 2015 | 5 | 0.040 |
Why?
| | Colorado | 1 | 2015 | 9 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2015 | 7 | 0.040 |
Why?
| | Cough | 1 | 2015 | 7 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2015 | 31 | 0.040 |
Why?
| | Emergency Medical Services | 1 | 2015 | 13 | 0.040 |
Why?
| | Primary Health Care | 1 | 2015 | 42 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 83 | 0.040 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 2 | 0.040 |
Why?
| | Economics, Hospital | 1 | 2015 | 3 | 0.040 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 8 | 0.040 |
Why?
| | Cost Savings | 1 | 2015 | 10 | 0.040 |
Why?
| | Gene Frequency | 1 | 2015 | 75 | 0.040 |
Why?
| | Program Evaluation | 1 | 2015 | 48 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2015 | 35 | 0.030 |
Why?
| | Asthma | 1 | 2015 | 136 | 0.030 |
Why?
| | Drainage | 1 | 2013 | 38 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 97 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2013 | 40 | 0.030 |
Why?
| | Rats | 2 | 2005 | 208 | 0.030 |
Why?
| | Diagnostic Test Approval | 1 | 2011 | 1 | 0.030 |
Why?
| | Tympanic Membrane | 1 | 2011 | 1 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2011 | 2 | 0.030 |
Why?
| | Administration, Topical | 1 | 2011 | 6 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2011 | 7 | 0.030 |
Why?
| | Otitis Media with Effusion | 1 | 2011 | 2 | 0.030 |
Why?
| | Administration, Oral | 1 | 2011 | 65 | 0.030 |
Why?
| | Recurrence | 1 | 2011 | 104 | 0.030 |
Why?
| | Cell Wall | 1 | 2010 | 1 | 0.030 |
Why?
| | Mycolic Acids | 1 | 2010 | 1 | 0.030 |
Why?
| | Pigments, Biological | 1 | 2010 | 1 | 0.030 |
Why?
| | Chaperonin 60 | 1 | 2010 | 1 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2010 | 3 | 0.030 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2010 | 2 | 0.030 |
Why?
| | Africa | 1 | 2010 | 2 | 0.030 |
Why?
| | Enzymes | 1 | 2010 | 5 | 0.030 |
Why?
| | Hot Temperature | 1 | 2010 | 4 | 0.030 |
Why?
| | Binding Sites | 2 | 2002 | 50 | 0.030 |
Why?
| | Bacterial Adhesion | 2 | 1999 | 2 | 0.020 |
Why?
| | Face | 1 | 2008 | 2 | 0.020 |
Why?
| | Cefoxitin | 1 | 2006 | 1 | 0.020 |
Why?
| | Doxycycline | 1 | 2006 | 1 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2006 | 1 | 0.020 |
Why?
| | Linezolid | 1 | 2006 | 2 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2006 | 3 | 0.020 |
Why?
| | Acetamides | 1 | 2006 | 2 | 0.020 |
Why?
| | Oxazolidinones | 1 | 2006 | 2 | 0.020 |
Why?
| | Clarithromycin | 1 | 2006 | 3 | 0.020 |
Why?
| | Mycobacterium fortuitum | 1 | 2006 | 2 | 0.020 |
Why?
| | Amikacin | 1 | 2006 | 3 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 43 | 0.020 |
Why?
| | Uterine Diseases | 1 | 2005 | 1 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2005 | 1 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 16 | 0.020 |
Why?
| | Models, Molecular | 1 | 2002 | 18 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 17 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 20 | 0.020 |
Why?
| | DNA, Kinetoplast | 1 | 2002 | 1 | 0.020 |
Why?
| | Antibodies | 1 | 2002 | 15 | 0.020 |
Why?
| | Antibodies, Protozoan | 1 | 2002 | 3 | 0.020 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2002 | 9 | 0.020 |
Why?
| | Protein Binding | 1 | 2002 | 49 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2002 | 18 | 0.020 |
Why?
| | Gene Expression | 1 | 2002 | 74 | 0.010 |
Why?
| | Blood Group Antigens | 1 | 2001 | 2 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2001 | 6 | 0.010 |
Why?
| | Intestinal Diseases | 1 | 2001 | 5 | 0.010 |
Why?
| | Hemagglutinins | 1 | 2001 | 1 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 14 | 0.010 |
Why?
| | Neisseria gonorrhoeae | 1 | 1999 | 1 | 0.010 |
Why?
| | Complement C1q | 1 | 1999 | 3 | 0.010 |
Why?
| | Cattle | 1 | 1999 | 26 | 0.010 |
Why?
| | Actins | 1 | 1999 | 5 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 67 | 0.010 |
Why?
| | Cytochalasin D | 1 | 1997 | 1 | 0.010 |
Why?
| | Nocodazole | 1 | 1997 | 1 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 7 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1997 | 68 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|